Acquisition by Mary Fenton of 150000 shares of Talaris Therapeutics subject to Rule 16b-3
TALSDelisted Stock | USD 2.98 0.10 3.25% |
Slightly above 61% of Talaris Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Talaris Therapeutics suggests that many traders are alarmed regarding Talaris Therapeutics' prospects. Talaris Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Talaris Therapeutics' earnings reports, geopolitical events, and overall market trends.
Talaris |
Filed transaction by Talaris Therapeutics Inc officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Talaris Therapeutics Fundamental Analysis
We analyze Talaris Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Talaris Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Talaris Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Talaris Therapeutics is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Talaris Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Talaris Therapeutics stock to make a market-neutral strategy. Peer analysis of Talaris Therapeutics could also be used in its relative valuation, which is a method of valuing Talaris Therapeutics by comparing valuation metrics with similar companies.
Peers
Talaris Therapeutics Related Equities
CNTB | Connect Biopharma | 6.32 | ||||
TIL | Instil Bio | 5.39 | ||||
CGEM | Cullinan Oncology | 2.33 | ||||
NUVB | Nuvation Bio | 1.49 | ||||
ACHL | Achilles Therapeutics | 0.47 | ||||
VOR | Vor Biopharma | 0.34 | ||||
CTMX | CytomX Therapeutics | 0.91 | ||||
ACET | Adicet Bio | 1.79 | ||||
ASMB | Assembly Biosciences | 1.91 | ||||
OVID | Ovid Therapeutics | 2.42 | ||||
EWTX | Edgewise Therapeutics | 2.60 | ||||
NXTC | NextCure | 2.99 | ||||
SPRO | Spero Therapeutics | 3.12 |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in Talaris Stock
If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |